

Devices for Atrial Fibrillation screening and prevention of cardiovascular diseases.

Good news for your heart

Microlife is a world leader in the development and production of diagnostic devices intended for both home and professional use. The blood pressure monitors with AFIB technology have successfully passed the most rigorous clinical certifications and feature patented technologies allowing for the improvement of both measurement standards and patient compliance.

PATENTED TECHNOLOGIES	CLINICAL VALIDATIONS	WARRANTY
 Atrial Fibrillation detection US PATENT 7680532 US PATENT 7020514	 3 automatic measurements US PATENT 6,447,457 B1	5 years
	CLINICALLY TESTED BHS-BHS A/A protocol CLINICALLY TESTED in PREGNANCY CLINICALLY TESTED in DIALYSIS PATIENTS CLINICALLY TESTED with ATRIAL FIBRILLATION	



BP A200 AFIB

- Universal pre-formed cuff 22-42 cm
- 200 measurement memories
- USB port
- Suggested retail price:



WatchBP Home S

- 30 measurements memory
- Medical Consultation Reminder
- Suggested retail price:

**AVAILABLE FROM SUMMER 2011
IN LEADING PHARMACIES AND SPECIALIZED STORES**

Microlife AG
Eспенstrasse 139
9443 Widnau - Switzerland
www.microlife.com

microlife



Good news for your heart

Microlife presents Afib

Atrial Fibrillation
and blood pressure screening
in a click



microlife
A partner for people. For life.



Good news for your heart

The importance of Atrial Fibrillation screening for STROKE prevention.

Atrial Fibrillation is a heart rhythm disturbance that, if left untreated, could lead to slower blood flow. Reduced blood flow can cause clotting in major organs. These clots may travel towards the brain and cause stroke. The incidence of Atrial Fibrillation is about 1% in people of around 50 years of age, but it increases **up to 10% in people aged over 65**.

* In Europe around **4.5 million people are estimated to be affected with Atrial Fibrillation**, with about **300.000 new cases every year**.

* Atrial Fibrillation is **responsible for 20% of stroke cases**.

Stroke is the third leading cause of death, the **main cause of invalidity** and the **second leading cause of dementia in the general population**.

The risk of STROKE in people affected with Atrial Fibrillation is **three to five times higher than in the healthy population**.

Many people with AF often have no symptoms which makes it harder to detect for treatment. Screening and early detection of Atrial Fibrillation enables an effective treatment of the patient in order to prevent any possible complications such as stroke. Atrial fibrillation and hypertension are often correlated risk factors which need to be managed in order to effectively prevent cardiovascular diseases.

* Source: *Epidemiology of Stroke* - <http://www.strokecenter.org/prof/epide.htm>

The advantages of clinically validated, home use screening for Atrial Fibrillation:

- Enables early detection and treatment in risk patients
- Prevents possible complications such as stroke
- Reduces in-patient hospitalization and management costs
- Provides a cost efficient means for patients who can work together with the general practitioner with a single device to reduce the risk of cardiovascular diseases

AFIB (Atrial FIBrillation) Patented Technology for the early detection of Atrial Fibrillation.

US Patent 7680532, 7020514

State-of-the-art technology patented by **Microlife** allows for easy **Atrial Fibrillation screening** at home with a simple **blood pressure measurement**.


When an Atrial Fibrillation is detected during a measurement, the monitor signals the arrhythmia by displaying the AFIB logo.



- The AFIB logo will be displayed only if all of the 3 measurements detect the Atrial Fibrillation.
- When the AFIB logo is displayed, it is advisable to repeat the measurement after about 1 hour.
- If after 1 hour the Atrial Fibrillation is still detected, consult with your general practitioner for further testing.
- The measurement in the single mode does not allow for the detection of Atrial Fibrillation.

The AFIB technology achieved significant clinical validation results thanks to its high accuracy obtained through **3 consecutive measurements (MAM technology)**.

AFIB technology detects AF with a **high sensitivity (97-100%) and specificity (89%)**, as demonstrated by two recent comparison studies with electrocardiogram involving 500 patients.



	No of Patients	Age (years)	hypertensive patient	diabetic patient	cardiac patient	sensitivity (%)	specificity (%)
Stergiou	72	49-92	63%	15%	40%	100	89
Wiesel	405	34-98	52%	15%	44%	97	89

Stergiou GS, Karpettas N, Protogerou A, Nasothimiou EG, Kyriakidis M. - Diagnostic accuracy of a home blood pressure monitor to detect atrial fibrillation. *J Hum Hyperten* 2009;23:654-658.

Wiesel J, Fitzig L, Herschman Y, Messineo FC. - Detection of atrial fibrillation using a modified Microlife blood pressure monitor. *Am J Hypertens* 2009;22:848- 852.

